Colorectal Cancer – VJRegenMed

Treating colorectal cancer with CoupledCAR technology

Simon Ng — Thu, 03 Mar 2022 17:46:22 +0000

Christopher Ballas, PhD, Innovative Cellular Therapeutics, Rockville, MD, comments on progress in evaluating CoupledCAR, a chimeric antigen receptor (CAR) T-cell therapy designed for solid tumors, in colorectal cancer. The investigational CAR T-cell therapy targets the antigen guanylate cyclase 2C (GCC) and whilst it is also expressed in normal tissue, targeting GCC has proven to be safe. Institutional Review Board (IRB) trials have demonstrated promising efficacy in patients in the third line setting. Dr Ballas additionally highlights how the target can be altered to treat alternative indications such as thyroid and prostate cancer. This interview took place at Advanced Therapies Week 2022.

Adapting to challenges in manufacturing cell therapies for solid tumors

Simon Ng — Thu, 03 Mar 2022 17:46:20 +0000

Whilst chimeric antigen receptor (CAR) T-cell therapies have been successful in hematological malignancies, solid tumors remain an unmet need especially in patients with colorectal cancer. Christopher Ballas, PhD, Innovative Cellular Therapeutics, Rockville, MD, describes strategies to increase the production of CAR T-cell therapies for solid tumors. Decentralized manufacturing and automation will enable therapies to be produced in a shorter timeframe, improve quality control, and facilitate the regulatory process. However, logistics and cost are issues that still need to be addressed. This interview took place at Advanced Therapies Week 2022.

Allogeneic NKX101 in liver cancer

Simon Ng — Tue, 26 Oct 2021 09:52:59 +0000

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, discusses NKX101 in solid tumor indications. NKX101, an allogeneic NKG2D receptor chimeric antigen receptor (CAR) natural killer (NK) cell therapy, is currently being assessed in patients with relapsed/refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndromes (MDS) in a Phase I trial (NCT04623944). In addition to AML and MDS, NKX101 use is being extended to liver localized tumors including hepatocellular carcinoma (HCC) and metastatic colorectal cancer. Transarterial delivery will enable successful trafficking of the cell therapy to the tumor by concentrating NKX101 in the tumor. This interview took place at Meeting on the Mesa 2021.

A non-gene edited approach to allogeneic CAR-T development

admin_vjr_user — Sat, 10 Apr 2021 10:58:00 +0000

Filippo Petti, CEO/CFO, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the benefits of using a non-gene edited approach for the development of single-vector, allogeneic CAR-T cancer therapies. Preliminary data from the ongoing Phase I alloSHRINK study (NCT03692429) in patients with colorectal cancer treated with CYAD-101, a natural killer group 2D (NKG2D) CAR-T candidate encoding the T cell receptor inhibitory molecule (TIM), has highlighted the potential of this approach. He also introduces the recently launched Phase I IMMUNICY-1 study (NCT04613557) investigating CYAD-211, a short hairpin RNA (shRNA)-based CAR T therapy, in patients with multiple myeloma. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC

admin_vjr_user — Wed, 10 Mar 2021 19:30:20 +0000

David Gilham, PhD, Celyad Oncology, Mont-Saint-Guibert, Belgium, describes the ongoing Phase 1 alloSHRINK trial (NCT03692429) evaluating CYAD-101, a non-gene edited allogeneic CAR-T cell therapy that targets the natural killer group 2D (NKG2D) receptor, in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC). Preliminary data in 15 patients with MSS mCRC suggests that CYAD-101 therapy may result in improved clinical responses and progression-free survival, although studies are ongoing and further data is required to confirm the benefits in this patient group. This interview took place during the CAR-TCR Summit Europe 2021.